Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 25
- Registration Number
- NCT00890552
- Locations
- 🇺🇸
Stanford University Cancer Institute, Stanford, California, United States
A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q
- Conditions
- Interventions
- First Posted Date
- 2009-04-22
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 85
- Registration Number
- NCT00885508
- Locations
- 🇫🇷
Centre henri Mondor, Creteil, France
🇫🇷CH Angers, Angers, France
🇫🇷hopital Victor Dupouy, Argenteuil, France
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 27
- Registration Number
- NCT00884546
- Locations
- 🇺🇸
City Of Hope National Medical Center, Duarte, California, United States
🇺🇸The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
- First Posted Date
- 2009-04-17
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 50
- Registration Number
- NCT00883623
- Locations
- 🇩🇪
University Clinic Heidelberg, Heidelberg, Germany
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Conditions
- Interventions
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 254
- Registration Number
- NCT00875667
- Locations
- 🇵🇱
Malopolskie Centrum medyczne s.c., Kraków, Poland
🇳🇱Isala Klinieken, Zwolle, Netherlands
🇧🇪UZ Brussels, Brussel, Belgium
The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 36
- Registration Number
- NCT00874978
- Locations
- 🇬🇧
King's College Hospital NHS Foundation Trust, London, United Kingdom
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 22
- Registration Number
- NCT00860457
- Locations
- 🇺🇸
Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 30
- Registration Number
- NCT00848328
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2014-04-04
- Target Recruit Count
- 30
- Registration Number
- NCT00847639
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
- Conditions
- Interventions
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 247
- Registration Number
- NCT00843882
- Locations
- 🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸Kaiser Permanente South Bay, Harbor City, California, United States
🇺🇸Springfield Memorial Hospital, Springfield, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.